Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug;11(8):e00205.
doi: 10.14309/ctg.0000000000000205.

Response to Chen et al

Liangtao Ye  1   2   3 , Florian P Reiter  1   2 , Markus Guba  4 , Enrico N De Toni  1   2
Affiliations
Comment

Response to Chen et al

Liangtao Ye et al. Clin Transl Gastroenterol. 2020 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Guarantor of the article: Enrico N. De Toni, MD.

Specific author contributions: The 4 authors equally contributed to this letter, which is written on behalf of all the authors of the original manuscript.

Financial support: None to report.

Potential competing interests: E.D.T. has served as a paid consultant for AstraZeneca, Bayer, BMS, EISAI, Eli Lilly & Co, Pfizer, IPSEN, and Roche. He has received reimbursement of meeting attendance fees and travel expenses from Arqule, BMS, Bayer, Celsion and Roche, and lecture honoraria from BMS and Falk. He has received third-party funding for scientific research from Arqule, AstraZeneca, BMS, Bayer, Eli Lilly, and Roche.

Figures

Figure 1.
Figure 1.
Effect of OLFM4 staining according to its cellular distribution in patients without extrahepatic tumors. (a) Tumor-related survival according to the presence or absence of cytoplasm staining for OLFM4 or (b) according to a semiquantitative evaluation of cytoplasm staining. (c) Tumor-related survival according to the presence or absence of membrane staining for OLFM4 or (d) according to a semiquantitative evaluation of membrane staining. (e) Tumor-related survival according to overall OLFM4 staining. +: Censored cases.
See this image and copyright information in PMC

Comment on

References

    1. Chen W-Y, Diao Y-K, Jia H-D, et al. Association between olfactomedin 4 and postoperative prognosis in patients with early-stage Hepatocellular carcinoma. Clin Transl Gastroenterol 2020;11(6):e00163. - PMC - PubMed
    1. Ye L, Kriegl L, Reiter FP, et al. Prognostic significance and functional relevance of olfactomedin 4 in early-stage hepatocellular carcinoma. Clin Transl Gastroenterol 2020;11(1):e00124. - PMC - PubMed
    1. De Toni EN, Schlesinger-Raab A, Fuchs M, et al. Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: A population-based study. Gut 2020;69(1):168–176 - PMC - PubMed
    1. Gerbes A, Zoulim F, Tilg H, et al. Gut roundtable meeting paper: Selected recent advances in hepatocellular carcinoma. Gut 2018;67(2):380–8. - PMC - PubMed
    1. Kamarajah SK, Frankel TL, Sonnenday C, et al. Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with hepatocellular carcinoma (HCC): A Surveillance, Epidemiology, End results (SEER) analysis. J Surg Oncol 2018;117(4):644–50. - PubMed